CBS-0550
# CBS-0550

CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid $CB_2$ receptor agonist, with 1400x selectivity for $CB_2$ over the related $CB_1$ receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects. A number of related compounds have been developed with similar properties.

